Melatonin Prevents Chondrocyte Matrix Degradation in Rats with Experimentally Induced Osteoarthritis by Inhibiting Nuclear Factor-κB via SIRT1

Nutrients. 2022 Sep 24;14(19):3966. doi: 10.3390/nu14193966.

Abstract

Osteoarthritis (OA) is a common degenerative joint disease characterized by an imbalance of cartilage extracellular matrix (ECM) breakdown and anabolism. Melatonin (MT) is one of the hormones secreted by the pineal gland of the brain and has anti-inflammatory, antioxidant, and anti-aging functions. To explore the role of MT in rats, we established an OA model in rats by anterior cruciate ligament transection (ACLT). Safranin O-fast green staining showed that intraperitoneal injection of MT (30 mg/kg) could alleviate the degeneration of articular cartilage in ACLT rats. Immunohistochemical (IHC) analysis found that MT could up-regulate the expression levels of collagen type II and Aggrecan and inhibit the expression levels of matrix metalloproteinase-3 (MMP-3), matrix metalloproteinase-13 (MMP-13), and ADAM metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4) in ACLT rats. To elucidate the mechanism of MT in protecting the ECM in inflammatory factor-induced rat chondrocytes, we conducted in vitro experiments by co-culturing MT with a culture medium. Western blot (WB) showed that MT could promote the expression levels of transforming growth factor-beta 1 (TGF-β1)/SMAD family member 2 (Smad2) and sirtuin 2-related enzyme 1 (SIRT1) and inhibit the expression of levels of phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibi-tor (p-p65) and phosphorylated IκB kinase-α (p-IκBα). In addition, WB and real-time PCR (qRT-PCR) results showed that MT could inhibit the expression levels of MMP-3, MMP-13, ADAMTS-4, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) in chondrocytes induced by interleukin-1β (IL-1β), and up-regulate the expression of chondroprotective protein type II collagen. We found that in vivo, MT treatment protected articular cartilage in the rat ACLT model. In IL-1β-induced rat chondrocytes, MT could reduce chondrocyte matrix degradation by up-regulating nuclear factor-kB (NF-κB) signaling pathway-dependent expression of SIRT1 and protecting chondrocyte by activating the TGF-β1/Smad2 pathway.

Keywords: NF-κB pathway; SIRT1; TGF-β1/Smad2 pathway; chondrocytes; melatonin.

MeSH terms

  • Aggrecans / metabolism
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / metabolism
  • Cartilage, Articular* / metabolism
  • Chondrocytes / metabolism
  • Collagen Type II / metabolism
  • Cyclooxygenase 2 / metabolism
  • I-kappa B Kinase / metabolism
  • Interleukin-1beta / metabolism
  • Matrix Metalloproteinase 13 / genetics
  • Matrix Metalloproteinase 13 / metabolism
  • Matrix Metalloproteinase 3 / metabolism
  • Melatonin* / metabolism
  • NF-KappaB Inhibitor alpha / metabolism
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Osteoarthritis* / drug therapy
  • Osteoarthritis* / metabolism
  • Rats
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism
  • Sirtuin 2 / metabolism
  • Thrombospondins / metabolism
  • Thrombospondins / therapeutic use
  • Transforming Growth Factor beta1 / metabolism
  • Transforming Growth Factors / metabolism
  • Transforming Growth Factors / therapeutic use

Substances

  • Aggrecans
  • Anti-Inflammatory Agents
  • Antioxidants
  • Collagen Type II
  • Interleukin-1beta
  • NF-kappa B
  • Thrombospondins
  • Transforming Growth Factor beta1
  • NF-KappaB Inhibitor alpha
  • Transforming Growth Factors
  • Nitric Oxide Synthase Type II
  • Cyclooxygenase 2
  • I-kappa B Kinase
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinase 3
  • Sirt1 protein, rat
  • Sirtuin 1
  • Sirtuin 2
  • Melatonin